STERIS plc (NYSE: STE) — A Wide-Moat Sterilization Compounder at Its Cheapest Multiple Ever, Punished for Goodwill Optics and an Ethylene-Oxide Fear That Isn’t Really Its Own

Report date: 2026-07-10 · Coverage: Initiation Price (2026-07-09 close): ~$216 · Market cap: ~$20.4B · Enterprise value: ~$23.4B (net debt ~$1.49B, ~0.94x EBITDA) FY2026 (ended Mar-2026): revenue $5,935.9M (+8.7%, +7.3% cc-organic) · adj. dil. EPS $10.17 (+10%) · GAAP EPS $7.93 · FCF ~$972M · GM 44.2%

⚡ Claude’s Take

This block is the author’s own subjective opinion and general information — not investment advice. The analysis that follows takes no position and carries no price target; this block is the single exception.

Verdict: HOLD / accumulate — leaning the most constructive of the quality-compounders I’ve looked at this cycle. A genuine wide-moat #1 franchise at its cheapest multiple in a decade, de-rated on a set of misunderstandings rather than a business break. Accumulate here at ~$216 (≈19x forward adjusted EPS, ~14.7x EV/EBITDA) and add on further healthcare-rotation weakness toward the high-$180s–$200; fair-value zone ~$255–285 (≈22–25x FY27 adj. EPS of ~$11.20). Not a short — you don’t short the world’s #1 sterilization toll-road, de-levered, buying back stock, at the low end of its historical multiple. Conviction: medium, tilting good on value.

Tag: “Cheapest it’s ever been, punished for a goodwill number that isn’t real economics and an ethylene-oxide fear that belongs to its competitor.”

STERIS is a genuinely wide-moat business hiding behind two optical problems the market has mistaken for fundamental ones. The franchise is excellent: the global #1 in infection prevention and sterilization, 78.9% recurring razor/blade revenue (service + consumables), a stable ~44% gross margin, +7.3% constant-currency organic growth in a record FY2026, and — the crown jewel — Applied Sterilization Technologies (AST), a 46%-operating-margin, FDA-validated, capacity-constrained outsourced-sterilization duopoly (with Sotera) whose customers literally write STERIS’s sterilization process into their device registrations, making switching slow, costly, and rare. Strip the acquired-intangible layer and the underlying business earns roughly 27% return on tangible invested capital (~34% on a cash basis). This is a real compounder.

The two optical problems: First, the headline ROIC of ~9% looks WACC-ish and un-moaty — but it is a pure goodwill artifact of the 2021 Cantel deal ($4.6B, which loaded ~$5.8B of goodwill and intangibles onto invested capital; tangible book is just ~$14/share versus ~$74 book). The economically-correct lens is EV/EBITDA, adjusted EPS, and FCF — and GAAP EPS itself is understated by ~$2.24/share of non-cash, finite-lived Cantel amortization, so the “27x P/E” screens are misleading; the real number is ~21x trailing / ~19x forward on adjusted EPS. Second, the ethylene-oxide (EO) overhang is largely Sotera’s, not STERIS’s — STERIS’s marquee EO liability is a ring-fenced ~$48M legacy settlement from a facility it operated in 2005–2008 (settled, cash running off), and the EPA’s 2026 rollback of the 2024 EtO rule is, in management’s words, a financial non-event (“we’re pretty much fully spent”). The real EO risk is sector headline contagion from Sterigenics/Sotera’s Willowbrook litigation, not a quantified STERIS threat.

Put those together and you have a wide-moat compounder that made a fresh all-time high of ~$267 in January 2026, then de-rated ~25% to ~$216 — while the business beat (the stock rose +4.5% on the FY26 print, and management raised the buyback to $1B and the dividend for a 20th straight year). The de-rate is peer multiple compression (healthcare capital rotating to AI/tech) plus growth-normalization optics (organic easing from post-Cantel high-single/low-double toward mid-single, with an AST customer inventory de-stock — not end-demand — softening H2) — not a fundamental crack. At ~19x forward adjusted EPS and ~14.7x EV/EBITDA (versus a 17–25x EV/EBITDA history), the price embeds only ~5–6% durable growth against a business guiding +9–11% EPS. Framing: an abandoned quality-defensive medtech, cheap on a misunderstanding — the value end of the GGG/ROL “compounder in the penalty box” trade, and the clearest of the three.

What flips me decisively bullish: the AST de-stock ending (customer volumes reaccelerating) and the healthcare-quality factor rotating back into favor — either re-rates a ~19x name toward its mid-20s norm. What flips me bearish: organic settling at 3–4% (proving the normalization is structural, not a de-stock), an EO tort escalation that pierces the ring-fence, or the balance sheet’s dry powder (“kissed a lot of frogs, not many princesses”) funding a second full-priced Cantel. The honest risk is not a blow-up — it’s dead money until the rotation turns, which the 3-year flat return already attests.

📈 Stock Price Action — Five-Year Event Map

Factual price history — no recommendation, no price target. Price moves are Fact; attributed drivers are Interpretation.

Over the trailing ~60 months STERIS round-tripped a rate-shock bear and then made a fresh record before de-rating: from a five-year low of ~$154.8 (Sep-2022) to an all-time high of ~$267.2 (Jan-16-2026), and back to ~$216 now — ~19% below the peak (and ~25% off intraday), a fresh multi-quarter low. The 52-week range is ~$199–$267; the stock sits just below its 200-day EMA (~$227), a mild recent downtrend. Beta is 0.57 — a low-vol defensive whose price is driven more by the healthcare/rate factor than by company news. Crucially, this is not an old-high grind: STE made its record this year and de-rated coincident with the healthcare rotation, while fundamentals kept compounding.

Cycle narrative. (1) STERIS closed the transformational Cantel deal and rode the elective-procedure reopening to ~$233. (2) The 2022 rate shock produced the period’s only real drawdown — a multiple event on a long-duration defensive, not a fundamental one. (3) It recovered on procedure normalization and margin recovery. (4) 2024 was choppy/flat around the disciplined Dental divestiture. (5–6) A 2025 beat-and-raise cadence plus a flight to defensive quality carried it to a fresh all-time ~$267 in January 2026. (7) The dominant recent move is the ~25% H1-2026 de-rating: a broad healthcare/medtech rotation out (capital chasing AI/tech), amplified by growth-normalization optics and EO sector-headline noise — taking STE to its cheapest P/E percentile in a decade while the business beat and raised. (Price moves are FACT from the five-year price series; drivers are INTERPRETATION cross-referenced to earnings dates, 8-K events, and the news feed. The two big moves — 2022 and 2026 — were factor/multiple events, not fundamental breaks.)

1. Executive Summary

STERIS is the global #1 in infection prevention and sterilization, serving hospitals, medical-device makers, and pharmaceutical companies through three segments (FY2026): Healthcare $4,208.6M (70.9% of revenue; 24.6% operating margin) — sterilizers, washers, surgical tables, sterility-assurance consumables, endoscopy/GI reprocessing, and service; Applied Sterilization Technologies (AST) $1,138.5M (19.2%; 46.1% margin) — outsourced contract sterilization of medical devices across a >60-facility, technology-neutral network (gamma, E-beam, X-ray, EO); and Life Sciences $588.8M (9.9%; 42.6% margin) — sterilization, consumables, and VHP for pharma. Revenue is 78.9% recurring (service + consumables), gross margin ~44%, and FY2026 was a record — +8.7% reported, +7.3% constant-currency organic, with adjusted EPS of $10.17 (+10%).

This is a genuine wide-moat compounder — the moat is just masked by goodwill. The advantages are multi-source (Greenwald): Healthcare’s razor/blade installed-base lock-in and #1/#2 share; AST’s regulatory lock-in (a device maker’s sterilization process is written into its FDA registration, so switching provider requires costly re-validation) inside a capacity-constrained duopoly; and Life Sciences’ aseptic-validation captivity. The financial proof is in the 46%/43% AST/Life-Sciences margins, the ~79% recurring mix, and ~30% incremental margins. The headline that misleads: consolidated ROIC of ~9% ≈ WACC — but that is a pure artifact of the 2021 Cantel deal, which loaded ~$5.8B of goodwill and intangibles onto invested capital (tangible book is ~$14/share versus ~$74 book). Strip that layer and the underlying business earns ~27% return on tangible invested capital (~34% cash) — the same “good business wearing a goodwill-diluted headline” pattern as SS&C, GXO, and Descartes. GAAP EPS is likewise understated by ~$2.24/share of non-cash, finite-lived Cantel amortization; the economically-correct lens is adjusted EPS, EV/EBITDA, and FCF.

The stock is at its cheapest valuation in a decade, and the de-rating is a misunderstanding, not a break. From a January-2026 all-time high of ~$267, STE de-rated ~25% to ~$216 — the 2nd percentile of its own decade P/E history (composite 21st), ~14.7x EV/EBITDA (down from a 17–25x range), and ~19x forward adjusted EPS. The drivers are optical: peer multiple compression as healthcare capital rotated to AI/tech (KeyBanc cut its target “given lower peer multiples” while keeping Overweight); growth normalizing from post-Cantel highs toward mid-single-digits, with an AST customer inventory de-stock (not end-demand) softening H2; and EO sector headline contagion from Sotera’s litigation — none of which is a STERIS fundamentals problem (the stock rose +4.5% on the FY26 print). STERIS’s own EO exposure is ring-fenced and provisioned; the EPA rule rollback is a financial non-event.

Capital allocation has pivoted shareholder-friendly, and the balance sheet is under-levered. Net debt fell from ~$3.0B post-Cantel to ~$1.49B (0.94x EBITDA, versus a 2–2.5x target); management doubled the buyback authorization to $1.0B (May-2026) with a $200–300M/year commitment, raised the dividend for a 20th consecutive year, and prunes disciplined bolt-ons. The one debated blemish is Cantel itself — a full-priced, per-share-dilutive transformational deal — but the assets are genuine regulatory-locked toll-roads, the integration succeeded, and the Dental divestiture ($787.5M) was clean pruning.

The forward question is not quality — it is whether you are paid to wait for the healthcare-quality rotation to turn and the AST de-stock to end. At ~19x forward adjusted EPS for a 79%-recurring, wide-moat, +7%-organic #1 franchise guiding +9–11% EPS, the embedded expectations (~5–6% growth) sit below the business’s own algorithm — a favorable setup, with the honest risk being dead money until sentiment turns, plus a monitorable EO tort tail. No recommendation or price target appears below; valuation is treated as embedded expectations and scenarios.

2. Business Overview (§7.1)

What STERIS is. STERIS is the global leader in infection prevention and sterilization — the products and services that ensure surgical instruments, medical devices, and pharmaceutical products are sterile. Irish-domiciled and NYSE-listed, it operates three segments after divesting Dental (2024). It sells a razor/blade model: install capital equipment (sterilizers, washers, surgical tables) and validated processes, then earn recurring, high-margin consumables and service on the installed base — 78.9% of revenue is recurring (service 48.4% + consumables 30.5%); capital equipment is only ~21%.

The three segments (FY2026) [FACT — FY2026 10-K, Note 13 segment reconciliation]:

AST is the crown jewel. Though only 19% of revenue, AST is ~29% of pre-corporate segment profit at a 46.1% operating margin — the highest-margin, most-defensible, most-secular business in the portfolio. It runs a technology-neutral network of >60 facilities and is one of two scaled outsourced sterilizers (with Sotera/Sterigenics) in a capacity-constrained, FDA-validated market. It likely represents well over 40% of STERIS’s intrinsic value.

Cantel and Dental. The 2021 Cantel acquisition (~$4.6B) added endoscopy/GI, dental, and water treatment. STERIS then divested the weakest piece — Dental (to Peak Rock for ~$787.5M, May-2024) — a disciplined prune, redeploying proceeds to deleverage. Capital-equipment backlog is ~$490.7M (Healthcare + Life Sciences).

Verdict (§7.1). A high-recurring (~79%), diversified, #1-franchise infection-prevention leader with a genuinely differentiated crown jewel (AST) — a razor/blade toll-road model with strong, stable margins and mid-single-digit-plus organic growth.

3. Industry Dynamics (§7.2)

Structure. Infection prevention and sterilization is a non-discretionary, regulation-mandated, recurring, secularly-growing healthcare niche — driven by aging demographics, rising procedure volumes, the shift to single-use devices, and the outsourcing of sterilization. Demand is remarkably steady (it survived COVID’s elective-procedure shutdown and rebounded), which is why the group carries low betas and defensive multiples.

AST — a capacity-constrained duopoly (the key structural point). Outsourced medical-device sterilization is effectively a two-player market (STERIS and Sotera/Sterigenics), and it has the favorable Marathon supply side: capacity is FDA-validated and permit-limited, so new entrants cannot easily add supply, and >40% margins are not competed away. Device makers must validate their sterilization process with a specific provider and modality, then register it with the FDA — locking in the relationship. This is one of the better industry structures in all of healthcare.

The EO overhang — real but largely Sotera’s. Ethylene oxide (EO) is one of four AST modalities and the only viable sterilant for many devices. The sector has an overhang: the EPA’s 2024 EtO emissions rules, and — the headline driver — Sterigenics/Sotera’s Willowbrook, Illinois personal-injury litigation (settlements of ~$408M in 2023 and ~$30.9M/$34M in 2025). STERIS’s exposure is far smaller and ring-fenced: its marquee EO liability is a ~$48M settlement of Cook County claims tied to a facility it operated in 2005–2008 (settled March-2025, cash running off in FY27), and the EPA’s March-2026 proposed rollback of the 2024 rule is a financial non-event per management (“we’re pretty much fully spent on upgrading our facilities”). EO scarcity, if anything, helps AST pricing. The risk is monitorable sector headline contagion, not a quantified STERIS threat.

Verdict (§7.2): structurally good — one of the better niches in healthcare. Non-discretionary, regulation-mandated, recurring demand; a genuinely capacity-constrained, FDA-locked AST duopoly; and an EO overhang that is more sentiment than STERIS-specific P&L. The capital cycle favors the incumbent with validated capacity.

4. Competitive Position (§4 / §7.3)

A genuine wide moat, multi-sourced. In Greenwald’s taxonomy STERIS combines several barriers:

• Healthcare — switching costs + scale: the razor/blade installed base of sterilizers and washers pulls proprietary, validated consumables and service; hospitals standardize on STERIS and rarely switch mid-cycle. #1/#2 share spreads R&D, service network, and manufacturing.
• AST — regulatory lock-in + switching costs + scale (the strongest): a device maker’s sterilization process is written into its FDA registration; changing provider or modality requires costly, slow re-validation, so customers are sticky price-takers. Combined with a capacity-constrained, permit-limited network, this produces the 46% margin and its durability.
• Life Sciences — aseptic-validation captivity: pharma consumables and validated processes carry the same regulatory switching costs.

Financial proof — and the goodwill caveat. The moat shows up as a stable ~44% gross margin, ~79% recurring revenue, ~30% incremental margins, and 46%/43% AST/Life-Sciences margins. The one metric that understates the moat is consolidated ROIC (~9%): it is a goodwill artifact. The 2021 Cantel deal loaded ~$5.8B of goodwill and acquired intangibles onto invested capital (goodwill ~$4.19B + intangibles ~$1.62B; tangible book ~$14/share versus ~$74 book). Strip that layer and the underlying business earns ~27% return on tangible invested capital (~34% cash) — elite. This is the classic “good roll-up wearing a diluted headline ROIC” pattern (SS&C, GXO, Descartes): the price paid for Cantel absorbs the accounting spread, but the operating economics are excellent. Use EV/EBITDA, adjusted EPS, and FCF — not ROIC.

Versus peers. STERIS’s AST is Sotera’s economics (~high-40s margins, regulatory lock-in) inside a diversified, better-capitalized, lower-EO-concentration wrapper — Sotera (SHC) is an AST/Nelson-Labs pure-play, more levered, with negative book equity and the Willowbrook EO scars. Getinge, Ecolab, and Fortive are point competitors in pieces of Healthcare/Life Sciences but none has the full-line-plus-AST combination. Ecolab is the premium infection-prevention adjacent name (a Cantel-like ~13% consolidated ROIC from buying scale at full prices) at nearly double STE’s multiple.

Verdict (§7.3): a durable wide moat, best expressed in AST. The regulatory-locked, capacity-constrained AST duopoly is a genuine structural advantage; Healthcare and Life Sciences add razor/blade captivity. The moat is real, proven by margins and recurring mix, and understated by a goodwill-diluted ROIC that the market appears to be reading literally.

5. Growth History and Forward Opportunities (§5 / §7.4)

History. Revenue compounded from $3.11B (FY2021) to $5.94B (FY2026) — a ~14% CAGR, boosted by the Cantel step and a steady ~mid-single-digit-plus organic base. Adjusted EPS rose to $10.17 (FY2026, +10%). Organic growth has normalized from post-Cantel/post-COVID high-single/low-double-digits toward mid-single-digits (+7.3% cc in FY2026) — healthy, but enough of a step-down to remove the premium-multiple justification.

Forward drivers.

• Healthcare (+7.6% organic FY26, service +12%): the recurring service and consumables base compounds on a growing installed base; procedure volumes and capital-equipment replacement drive it.
• AST (+6.7% organic, but H2-soft): the secular outsourcing tailwind (medtech volume + validated capacity) is intact; the near-term softness is a customer inventory de-stock, not end-demand (“procedure rates still consistently growing”), plus a US-snowstorm hit (~150–200bps in Q4). Reacceleration as de-stock ends is the key swing.
• Life Sciences (+6.7% organic, capital +15% recovery): bioprocessing/pharma demand recovered off the destock trough.
• FY2027 guide: +6–7% cc-organic; adjusted EPS $11.10–$11.30 (+9–11%); EBIT margin +~50bps; FCF ~$850M.
• Optionality: an under-levered balance sheet (0.94x vs a 2–2.5x target) and a dormant M&A pipeline — dry powder for AST capacity expansion or bolt-ons, plus the new $1B buyback.

Verdict (§5/§7.4): durable, high-quality, high-single/low-double-digit adjusted-EPS growth — currently normalizing. The growth is real and value-creating (recurring, high-margin, regulatory-locked). The near-term optics (AST de-stock, tariff/tax friction) are cyclical, not structural; the FY27 guide of +9–11% EPS is the tell that the algorithm is intact.

6. Financial Quality (§7.5)

Read this on adjusted EPS and EV/EBITDA, not GAAP or ROIC — both are distorted by Cantel purchase accounting. GAAP diluted EPS was $7.93 in FY2026 versus adjusted $10.17 — a ~$2.24/share (~28%) gap that is 94% amortization of acquired intangibles ($265M, ~$2.68/share pretax), a non-cash, finite-lived charge from the 2021 Cantel deal that rolls off over time. GAAP understates cash earnings; adjusted EPS is the economically-correct lens (and FCF confirms it).

The ROIC artifact. Consolidated ROIC of ~9.3% ≈ WACC is a pure goodwill artifact: the Cantel deal loaded ~$5.8B of goodwill and intangibles onto invested capital (tangible BVPS ~$14 versus ~$74 book). Strip that layer and the underlying business earns ~27% return on tangible invested capital (~34% on a cash basis) — the moat is intact; only the price paid for it shows through the headline. Segment margins corroborate: AST 46.1%, Life Sciences 42.6%, Healthcare 24.6%.

FCF — strong and clean. FY2026 operating cash flow was $1,341M; capex ~$369M (~6.2% of revenue, elevated by high-return AST capacity build-out); free cash flow ~$972M (~100% of adjusted net income). SBC is modest (~$62M, ~1% of revenue). This is a clean, high-conversion cash generator; the FY27 FCF guide is ~$850M (a step-down on continued AST capacity investment — a good use of capital, not a deterioration).

Margins and operating leverage. Gross margin is a stable ~44%; consolidated operating margin has climbed from the Cantel-diluted 11.3% (FY22) to 18.6% (FY26), with segment-profit margin at 23.3% and incremental margins ~30%. FY26 EBIT margin rose +10bps despite ~$46M of tariffs (−80bps) and a higher tax rate (24.4%, cross-border withholding).

Balance sheet — under-levered. Net debt fell from ~$3.0B post-Cantel to ~$1.49B (0.94x EBITDA), versus a 2–2.5x target; interest coverage is ~26x. This is a fortress-adjacent balance sheet with unused capacity.

Verdict (§7.5): a high-quality underlying business (~27–34% RoTIC) wearing a goodwill-diluted ~9% consolidated ROIC. Adjusted EPS, EV/EBITDA, and FCF are the right metrics, and on all three the quality is evident: ~79% recurring, ~44% gross margin, ~100% FCF conversion, under-levered. The GAAP and ROIC optics are the misunderstanding, not the reality.

7. Capital Allocation (§7.6)

A shareholder-friendly pivot on an under-levered balance sheet. After years of de-levering from the Cantel deal, STERIS’s FY2026 capital-allocation posture turned decisively more shareholder-friendly: net debt down to 0.94x EBITDA, a doubled buyback authorization to $1.0B (May-2026, with a $200–300M/year commitment versus the prior anti-dilution-only stance), a 20th consecutive annual dividend increase (~30% payout, ~1.1% yield), and disciplined bolt-on M&A only (~$20M in FY2026). FY26 repurchases were ~$225M (~$250/share).

The Cantel verdict (Capital Returns lens). The 2021 Cantel deal (~$4.6B, partly ~15M shares issued at a peak multiple) is the one debated blemish: it tripled goodwill/intangibles and collapsed ROE to 4.6% (FY22). The honest verdict is “paid full price for a good business” — per-share-dilutive on returns, value-neutral operationally. It is not a Marathon asset-growth disaster: the assets acquired are genuine regulatory-locked toll-roads (endoscopy, the water/Life-Sciences pieces), the integration succeeded (the single-use-scope fear that spooked the deal never materialized), and the underlying compounding is intact. The low headline ROIC is the price paid showing through, not an integration failure.

Disciplined pruning and deleveraging. The Dental divestiture ($787.5M, May-2024) — selling the weakest Cantel-acquired segment to Peak Rock — was a clean, value-accretive prune that funded deleveraging. This is the good pattern: buy a diversified platform, keep the toll-roads, sell the low-return piece.

Incentives and governance. Compensation is well-aligned — the CEO’s pay is ~90% variable, the annual bonus keys on Adjusted EBIT and FCF, and the LTIP uses premium-struck options (110% strike, 4-year) — a genuine bar. Leadership is stable (CEO Dan Carestio; a CFO succession Tokich→Burton in FY26). Insider Form 4 activity is routine grants around the AGM — no open-market buys, no unusual selling; a neutral signal.

The watch-item. The under-levered balance sheet plus a dormant M&A pipeline (“kissed a lot of frogs, not many princesses”) is dry powder that could fund either accretive buybacks/bolt-ons (good) or a second full-priced transformational deal (the Cantel risk). So far, the $1B buyback signals the former.

Verdict (§7.6): intelligent-but-once-expensive. Cantel was a full-priced, per-share-dilutive deal that impaired optical returns without breaking the business; everything since — the Dental prune, the deleveraging, the 20-year dividend streak, the $1B buyback, disciplined bolt-ons, and returns-linked comp — is a clear net positive. Good stewards, one expensive deal in the rear-view.

8. Changes and Headwinds — Last Two Years (§7.7)

Strategic / operational (mostly strengthening).

• Dental divested (May-2024, $787.5M): disciplined pruning of the weakest Cantel segment.
• Cantel fully digested: the feared single-use-endoscope disruption did not materialize; the platform is integrated.
• De-levered from ~$3.0B to ~$1.49B net debt (0.94x); interest expense $144M→$61M.
• Life Sciences/bioprocessing recovered off the 2023–24 destock trough (capital +15% in FY26).
• Capital-allocation pivot: doubled buyback to $1.0B; 20th straight dividend raise.
• Record FY2026: +7.3% cc-organic, adjusted EPS $10.17 (+10%); FY27 guide +9–11% EPS. Leadership stable (Carestio; CFO Tokich→Burton).

Headwinds / what weakened the stock narrative.

• Organic normalization: growth easing from post-Cantel highs toward mid-single-digits removed the premium-multiple justification.
• AST H2-FY26 choppiness: a med-device customer inventory de-stock (not end-demand) plus US snowstorms softened AST.
• Tariff/tax friction: ~$46M tariffs (−80bps) and a higher 24.4% tax rate.
• EO tort tail + sector headline contagion: STERIS’s own EO liability is ring-fenced/provisioned (~$48M legacy settlement; EPA rollback a non-event), but Sotera/Sterigenics litigation keeps a sentiment overhang on the sub-sector.
• The de-rating itself: a broad healthcare/medtech rotation out (capital to AI/tech) compressed the multiple to a decade low — while the business beat (STE rose +4.5% on the print).

Verdict (§7.7): the business is arguably better than two years ago; the stock de-rated on multiple compression and growth-normalization optics, not a fundamentals break. Operationally the period strengthened quality (Dental prune, Cantel digested, de-levered, Life Sciences recovered, buyback initiated, record year). What weakened is the narrative (organic normalization, AST de-stock, tariff/tax, EO headline contagion) — the core “quality-on-sale versus value-trap” tension.

9. Risk Analysis (§7.8)

Overall risk read: the dominant risks are regime/dead-money (the multiple staying compressed until healthcare rotates back), growth normalization proving structural rather than a de-stock, and the EO tort tail. None is a balance-sheet or franchise-break risk; the under-levered, diversified, non-discretionary profile makes a permanent impairment highly unlikely. The realistic bad outcome is continued dead money, not a blow-up.

10. Valuation Discussion (§7.9)

Use adjusted EPS, EV/EBITDA, and FCF — GAAP P/E and ROIC are distorted by Cantel purchase accounting. At ~$216 (~94.5M shares, market cap ~$20.4B; net debt ~$1.49B → EV ~$23.4B) against FY2026 EBITDA ~$1.59B, adjusted EPS $10.17, and FCF ~$972M: EV/EBITDA ~14.7x, adjusted P/E ~21.2x trailing (~19.2x on the FY27 guide midpoint of ~$11.20), EV/Sales 3.9x, FCF yield ~4.5%, dividend yield ~1.1%. GAAP P/E of ~27x is misleadingly high (the ~$2.24/share Cantel amortization). On the own-history percentiles, STE is at the 2nd percentile on P/E and the 21st composite — its cheapest in a decade — and EV/EBITDA has compressed from 25.7x (FY22) to 14.7x, ~43%.

Comps — re-rated to the low end of quality medtech.

STERIS at 14.7x EV/EBITDA sits mid-pack — below premium ECL/SYK (~21x), in line with RMD, above cheaper MDT/BDX and levered SHC — and below its own 17–25x history. It is re-rated to the low end of quality medtech, but the differentiator is quality-adjusted: for a 79%-recurring, wide-moat, +7%-organic #1 franchise with the AST crown jewel, ~14.7x EBITDA / ~19x forward adjusted EPS is attractive relative to the growth and durability on offer.

Embedded expectations. At ~14.7x EBITDA and ~19x forward adjusted EPS with a ~4.5% FCF yield and a low cost of equity (beta 0.57), the price embeds only ~5–6% durable growth — below STERIS’s own high-single/low-double-digit adjusted-EPS algorithm (FY27 guide +9–11%). The tape is pricing cautious, de-rated expectations, not heroics — the source of the opportunity if the algorithm holds.

Scenarios (3-year to ~FY2029, adjusted EPS; base FY26 ~$10.17 → guide-driven; NO price target; all ASSUMPTION):

• Bear (~$160–190): organic slows to 3–4% (normalization proves structural, not de-stock), margins flat → ~4–5% adj-EPS CAGR to ~$11.3–11.5; multiple de-rates further to ~12x EBITDA / ~18x adj P/E — the dead-money/value-trap outcome.
• Base (~$255–285): ~6% organic + margin + buyback → ~9% adj-EPS CAGR to ~$12.8–13.0; the multiple holds ~14–15x EBITDA / ~21–22x adj P/E — high-single-digit-plus total return.
• Bull (~$310–350): ~7–8% organic + AST/bioprocessing reacceleration + healthcare rotation returns → ~11–12% CAGR to ~$13.8–14.5; re-rate to ~16–17x EBITDA / ~25x adj P/E toward its own history.

Verdict (§7.9): genuinely cheap for the quality — the clearest value of the quality-compounder cohort. At the 2nd percentile of its own P/E history, ~19x forward adjusted EPS, and ~14.7x EBITDA for a wide-moat, 79%-recurring, +7%-organic #1 franchise guiding +9–11% EPS, the embedded expectations sit below the algorithm. The risk is timing (dead money until the rotation turns), not overpayment.

11. Variant Perception (§7.10)

Consensus. The sell-side is broadly constructive on the business but cut targets on multiples (KeyBanc to $269 “given lower peer multiples,” Overweight retained), and the stock trades at a decade-low valuation after a ~25% de-rate. The factor tape is an abandoned quality-defensive medtech: beta 0.57, negative relative strength on every horizon, dead-money 3-/5-year returns, positive Medical-Device/Life-Sciences/LowVol loadings but negative Momentum, Growth, and Beta — a low-vol #1-franchise that de-rated on the 2023–26 healthcare-out-of-favor rotation, with low idiosyncratic volatility (the moves are sector/factor-driven, not company-specific).

Strongest bull case. STERIS is a genuine wide-moat, #1-franchise, 79%-recurring compounder — with AST, a 46%-margin, FDA-validated, capacity-constrained sterilization duopoly — trading at its cheapest multiple in a decade on optical problems: a goodwill-depressed headline ROIC (the underlying business earns ~27% RoTIC), a GAAP EPS understated by non-cash Cantel amortization (~19x forward on the real number), and an EO overhang that is largely Sotera’s (STE’s is ring-fenced and provisioned). The business is beating (record FY26, +4.5% on the print, FY27 guide +9–11% EPS), de-levered to 0.94x, buying back $1B of stock, and raising the dividend for a 20th year. The embedded ~5–6% growth is below the algorithm. When the AST de-stock ends and healthcare rotates back into favor, a ~19x name re-rates toward its mid-20s norm — the clearest “quality-on-sale” setup in the cohort.

Strongest bear case. The de-rating may be justified: organic growth is structurally normalizing toward mid-single-digits (not just a de-stock), the premium multiple STE enjoyed for a decade is gone and may not return in a risk-on/AI regime, and the stock has been dead money for three years — a value-trap for the impatient. Consolidated ROIC really is ~9% (Cantel did pay full price and dilute per-share returns), the EO tort tail is genuinely unpredictable, and an under-levered balance sheet plus a frustrated M&A pipeline raises the risk of a second full-priced transformational deal. At ~19x forward for a mid-single-digit grower, “cheap versus its own history” may simply mean its history was too expensive.

The 3–5 assumptions that matter most:

1. Is the AST/organic softness a de-stock (transitory) or structural demand normalization?
2. Does the healthcare-quality factor rotate back into favor, or stay out (dead money)?
3. Does the EO tort tail stay ring-fenced, or does contagion/escalation pierce it?
4. Does management deploy the balance sheet accretively (buybacks/bolt-ons) or into another Cantel?
5. Does the market re-learn to value STE on adjusted EPS/EV-EBITDA (real economics) rather than GAAP P/E and ROIC (goodwill optics)?

What would falsify each side. Bull falsified: two-plus quarters of organic decelerating below ~4% with AST end-demand (not inventory) softening — the normalization is structural and ~19x is not cheap. Bear falsified: AST reaccelerates as the de-stock ends and adjusted EPS compounds ~9–11% on guide — at which point a decade-low multiple on a wide-moat compounder re-rates.

Net variant view. The market is reading two accounting/sentiment artifacts (goodwill-depressed ROIC, Sotera’s EO scar) as fundamental weakness and de-rating a genuine wide-moat compounder to its cheapest multiple ever while it beats and raises. The variant bet is that adjusted economics (~27% RoTIC, ~19x forward, +9–11% EPS) reassert over optics once the AST de-stock ends and healthcare rotates back — with the honest caveat that the timing is a regime call the tape has punished for three years.

12. Fact vs. Interpretation

13. Open Questions

1. AST de-stock — is the H2-FY26 softness inventory (transitory) or end-demand (structural)? Customer-volume data is the tell.
2. Rotation — does the healthcare-quality factor come back into favor, or does STE stay dead money?
3. EO tort tail — does the ring-fence hold, or does Sotera-style contagion/escalation reach STERIS?
4. Balance sheet — accretive buybacks/bolt-ons, or a second full-priced transformational deal?
5. Cantel amortization roll-off — the pace at which the GAAP–adjusted gap narrows (a mechanical GAAP-EPS tailwind).
6. AST capacity capex — the return on the elevated growth capex, and when FCF re-inflects.
7. Adjusted-EPS durability — does the +9–11% algorithm hold through the normalization?

14. What Must Be True (§14)

Bull case — what must be true:

1. The AST/organic softness is a de-stock (transitory) — AST reaccelerates toward mid-single-digits as customer inventory normalizes.
2. Adjusted EPS compounds ~9–11% on the algorithm (recurring razor/blade + AST + buyback), reaching ~$13+ within three years.
3. The market re-values STE on adjusted economics (~27% RoTIC, ~19x forward) rather than GAAP/ROIC optics, and/or the healthcare-quality factor rotates back.
4. The EO ring-fence holds and management deploys the balance sheet accretively.

Falsification test: AST reaccelerating with adjusted EPS on the +9–11% guide confirms the bull; organic decelerating below ~4% with AST end-demand softening falsifies it.

Bear case — what must be true:

1. Organic growth structurally normalizes to 3–4%, breaking the premium-growth justification.
2. The healthcare-quality multiple stays compressed (risk-on/AI regime), leaving STE dead money.
3. The EO tort tail escalates/contaminates, or management does a second full-priced Cantel.

Falsification test: a sustained AST/organic reacceleration with the multiple holding falsifies the bear; a second/third quarter of sub-4% organic with the multiple still de-rating confirms it.

Synthesis. Both cases agree STERIS is a wide-moat, #1 franchise; they disagree on whether the de-rate is a misunderstanding (opportunity) or a justified re-rating to a lower-growth reality (value-trap). Because the price embeds ~5–6% growth against a +9–11% guide, the moat is genuine, the EO fear is largely a competitor’s, and the ROIC/GAAP optics understate real economics, the asymmetry favors the patient accumulator — with the honest caveat that the reward requires the AST de-stock to end and/or the healthcare rotation to turn, which the three-year flat return shows the market has not yet rewarded. The realistic bad outcome is continued dead money, not a break.

15. Source Appendix

(Primary sources below.)

• STERIS plc FY2026 Form 10-K (filed 2026-05-29, year ended 2026-03-31) — segment revenue/margins (Note 13), recurring mix, AST/EO disclosure, adjusted-EPS reconciliation, capex/FCF, debt, legal (EO settlement).
• FY2025 / FY2024 Form 10-K — multi-year growth/margin trend, Cantel integration, Dental divestiture.
• Q2–Q4 FY2026 earnings/transcripts (via ROIC.ai) — organic by segment, AST de-stock, EO commentary, FY27 guidance, buyback pivot.
• DEF 14A proxy — compensation (Adjusted EBIT + FCF; premium-struck options), ownership.
• Form 8-Ks — Dental close (2024), FY26 results, $1B buyback authorization, dividend increases, CFO succession (Tokich→Burton).
• ROIC.ai — income statement, profitability ratios, enterprise value, valuation multiples (STE, and comps SHC/ECL/BDX/RMD/SYK/MDT); reconciled to filings.
• Market data — five-year adjusted price CSV (event map), valuation-index own-history percentiles (P/E 2nd, composite 21st), news feed.
• FactorsToday — factor loadings (Medical Device +0.43, Life Sciences, LowVol; beta 0.57), leaderboard (dead-money 3-/5-yr), related-stocks (MDT/SYK/RMD medtech).
• Business-quality / capital-cycle frameworks — Greenwald & Kahn, Competition Demystified; Marathon, Capital Returns (investment-research-frameworks skill).

Facts are cited to primary filings where possible; interpretations and assumptions are labeled as such throughout. Management commentary is treated as hypothesis and validated against filings, financials, and external data.

APPENDIX A — Standard Diligence Questionnaire — STERIS plc (NYSE: STE)

Supplemental to the analysis. Fact / Interpretation / Assumption labeled where it matters.

General

What thoughtful questions have other investors asked? Why did a #1 franchise de-rate to its cheapest P/E ever while beating? Is the ~9% ROIC evidence of a weak business, or a Cantel-goodwill artifact? Is GAAP EPS ($7.93) or adjusted ($10.17) the right number? Is the organic softness a de-stock (transitory) or structural? How exposed is STERIS to ethylene-oxide (EO) litigation vs. Sotera? Was Cantel value-destructive? Will the under-levered balance sheet fund buybacks or another big deal?

Cyclicality & Earnings Nature

Cyclical high or low? Near trend — non-discretionary, recurring demand; a near-term AST inventory de-stock, not a cyclical peak/trough. Not a cyclical.

External or internal? Growth is internal (installed base, AST outsourcing, pricing); recent softness is external (customer de-stock, snowstorms, tariffs).

How stable are revenues? Very — 78.9% recurring (service + consumables); survived COVID’s elective shutdown and rebounded.

Outlook for products/services? Structural mid-single-digit-plus growth (procedures, single-use devices, outsourcing); AST secular tailwind intact.

How big is the market? Large, growing infection-prevention/sterilization niche; AST a capacity-constrained duopoly.

Business Quality & Competitive Moat

More or less competitive? Stable — AST is an FDA-validated, permit-limited duopoly (vs Sotera); Healthcare/Life Sciences #1/#2.

How profitable (ROIC/ROE)? Consolidated ROIC ~9% ≈ WACC is a goodwill artifact; underlying RoTIC ~27% (~34% cash). Use adjusted EPS/EV-EBITDA/FCF.

How profitable is the industry / barriers? High barriers (regulatory lock-in, validated capacity, scale); AST >40% margins not competed away.

Easily understood? Mostly — razor/blade sterilization; the accounting (Cantel amort, goodwill ROIC) requires adjustment.

Undermined by foreign low-cost labor? No — regulated, validated, capital-and-network-intensive; not offshorable.

Do brands matter? Yes — STERIS is the trusted #1; validation/registration lock-in is the deeper moat.

Switching costs? High — especially AST (sterilization written into the customer’s FDA device registration; re-validation is costly/slow).

Financial Condition & Balance Sheet

Assets not on the balance sheet? The validated AST network, installed base, and customer registrations exceed book; tangible book (~$14/sh) understates economic value.

Off-balance-sheet liabilities? EO tort tail (largely provisioned; ~$48M legacy settlement); leases; no unusual items.

How conservative is the accounting? Clean; adjusted EPS backs out non-cash Cantel amortization (economically correct). SBC modest (~1% of sales).

How capex-hungry? Moderate — capex ~6.2% of revenue, elevated by high-return AST capacity build; recurring razor/blade otherwise light.

Capital Allocation & Management

How much FCF, how used? FCF ~$972M FY26 (~100% of adj NI). Priorities: AST capacity capex > dividend > buyback ($1B authorization) > bolt-ons.

Significant acquisitions? Cantel (2021, ~$4.6B — full price, per-share dilutive but integrated); post-Cantel bolt-ons only (~$20M FY26). Dental divested ($787.5M, 2024).

Buying back shares? Yes — pivoted to a $1B authorization + $200–300M/yr; FY26 ~$225M.

Issuing stock to insiders? No — modest SBC; Cantel issued ~15M shares in 2021 (one-time).

Compensation policy? Well-aligned — CEO ~90% variable; bonus on Adjusted EBIT + FCF; LTIP premium-struck options (110% strike).

Motivations of management? Stable (CEO Carestio; CFO Tokich→Burton succession); returns-linked comp; disciplined post-Cantel.

Valuation & Market Data

ADR, MLP, or K-1? No — an Irish plc common share listed on NYSE (ordinary shares, not an ADR); standard 1099. (Irish dividend-withholding generally exempt for US holders via treaty/DTC.)

Dividend policy? Raised for a 20th consecutive year; ~30% payout; ~1.1% yield.

How profitable? Elite underlying (AST 46%, LS 43%, Healthcare 25% margins; ~27% RoTIC); consolidated ROIC diluted by goodwill.

Net income vs. cash flow? FCF (~$972M) ≈ adjusted NI; GAAP NI understated by Cantel amortization. High earnings quality.

Risks & Downside

What would cause the stock to decline? Structural organic deceleration; the healthcare-quality multiple staying compressed; an EO tort escalation; a second full-priced deal.

Catastrophic loss risk? Very low — diversified, under-levered (0.94x), non-discretionary, #1 franchise.

Total loss? Effectively nil — the risk is dead money / de-rating, not a wipeout.

Recent News & Events

Has the environment changed? Stock yes (de-rated ~25% on rotation/optics); business no (record FY26, +9–11% EPS guide).

Significant acquisitions? Cantel (2021); bolt-ons since; Dental divested (2024).

Change in accounting policies? None material; Cantel intangible amortization rolls off over time (a mechanical GAAP tailwind).

Recent changes? $1B buyback (2026), CFO succession (Tokich→Burton), 20th dividend raise, EPA EtO rule rollback (a non-event for STE).

APPENDIX B — Source Appendix — STERIS plc (NYSE: STE)

Primary sources prioritized. Facts cited to filings where possible; interpretations/assumptions labeled in the memo. Access date: 2026-07-10.

Primary — SEC Filings (STERIS plc, CIK 0001757898)

• FY2026 Form 10-K (filed 2026-05-29; year ended 2026-03-31) — three-segment reporting (Healthcare / AST / Life Sciences), revenue and operating margins (Note 13), recurring-revenue mix, AST facility network and EO modality disclosure, adjusted-EPS reconciliation (intangible amortization), capex/FCF, debt schedule, legal proceedings (EO settlement). Local: output/STE/sources/10-K/2026-05-29_ste-20260331.htm.
• FY2025 / FY2024 Form 10-K — multi-year growth/margin trend, Cantel integration, Dental divestiture (discontinued ops). .../2025-05-29_ste-20250331.htm, .../2024-05-29_ste-20240331.htm.
• FY2026 10-Qs (Q2–Q4) — organic growth by segment, AST inventory de-stock, tariffs/tax, guidance. output/STE/sources/10-Q/.
• DEF 14A proxy — executive compensation (Adjusted EBIT + FCF metrics; premium-struck options 110% strike), ownership. output/STE/sources/DEF_14A/.
• Form 8-Ks — FY26 results (GlobeNewswire 2026-05-11), $1.0B buyback authorization (May-2026), Dental divestiture close (May-2024), dividend increases, CFO succession (Michael Tokich → Jason Burton). output/STE/sources/8-K/.
• Form 4s — insider read: routine code-A grants around the AGM; no open-market buys (code P), no unusual selling. EDGAR.

Primary — Earnings-Call Transcripts (via ROIC.ai)

• Q4/FY2026 (~May-2026) / Q3 (~Feb-2026) / Q2 (~Nov-2025) — organic by segment (Healthcare +7.6%, AST +6.7% H2-soft, Life Sciences +6.7%), AST customer inventory de-stock framing, EO regulatory commentary (“fully spent on facilities”), FY27 guidance (adj EPS $11.10–11.30, +9–11%), tariff/tax, capital-allocation pivot ($1B buyback). (CEO Dan Carestio; CFO Tokich→Burton.)

Quantitative Data Sources

• ROIC.ai — income statement, profitability ratios, enterprise value, valuation multiples (STE, and comps SHC/ECL/BDX/RMD/SYK/MDT); reconciled to filings (filings primary).
• Market data — five-year adjusted price CSV (event map); valuation-index own-history percentiles (P/E 2.16 pctile, P/S 30th, composite 21st); news feed (FY26 print, KeyBanc target cut). CSV local: output/STE/2026-07-10/_scratch/STE_price.csv.
• FactorsToday — factor loadings (Medical Device +0.43, Life Sciences +0.24, LowVol; negative Momentum/Growth; beta 0.57), leaderboard (dead-money y3 +0.6%/y5 +1.6%), related-stocks (MDT/SYK/RMD/GEHC/BAX medtech), specific-vol (~19.5%).
• EDGAR / edgar.sh — corpus enumeration; adjusted-EPS and tangible-book reconciliation.

Secondary — Press & Third-Party

• FY2026 results and FY2027 guidance — GlobeNewswire, 2026-05-11.
• KeyBanc target cut ($291→$269, Overweight retained, “lower peer multiples”) — 2026 (target not reproduced in the memo body per no-price-target rule).
• Ethylene-oxide regulatory (EPA EtO 2024 rule + 2026 proposed rollback) and Sotera/Sterigenics Willowbrook settlements — trade/regulatory press, 2024–2026.

Analytical Frameworks

• Greenwald & Kahn, Competition Demystified — moat taxonomy (switching costs + regulatory lock-in + scale; AST as the strongest), market-share/ROIC tests (and the goodwill-vs-tangible-return distinction).
• Marathon Asset Management (Edward Chancellor, ed.), Capital Returns — supply-side capital-cycle analysis (capacity-constrained AST duopoly), and the “paid full price for a good business” vs. asset-growth-disaster distinction (Cantel).
• (via the repository’s investment-research-frameworks skill.)